{"id":29787,"date":"2026-02-10T04:35:00","date_gmt":"2026-02-09T20:35:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=29787"},"modified":"2026-02-10T07:03:32","modified_gmt":"2026-02-09T23:03:32","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%88%a9%e5%a6%a5%e6%98%94%e5%8d%95%e6%8a%97%e6%b2%bb%e7%96%97%e6%88%90%e5%b9%b4%e6%82%a3%e8%80%85%e5%a4%8d%e5%8f%91%e6%80%a7%e8%82%be%e7%97%85","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=29787","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u5229\u59a5\u6614\u5355\u6297\u6cbb\u7597\u6210\u5e74\u60a3\u8005\u590d\u53d1\u6027\u80be\u75c5\u7efc\u5408\u5f81"},"content":{"rendered":"\n

Original Investigation <\/p>\n\n\n\n

Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial<\/h1>\n\n\n\n

Yoshitaka Isaka, Yusuke Sakaguchi, Maki Shinzawa, et al<\/h3>\n\n\n\n

JAMA 2025;334;(22):2011-2019.<\/h3>\n\n\n\n

doi:10.1001\/jama.2025.19316<\/h3>\n\n\n\n

Key Points<\/p>\n\n\n\n

Question<\/strong>  Does rituximab, compared with placebo, prevent relapse in adult patients with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome?<\/p>\n\n\n\n

Findings<\/strong>  In this randomized clinical trial that included 66 adults with either frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome, rituximab treatment significantly improved the relapse-free rate at week 49 compared with placebo (87.4% vs 38.0%).<\/p>\n\n\n\n

Meaning<\/strong>  In adult patients with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome, these findings support rituximab for reducing the relapse rate of nephrotic syndrome.<\/a><\/p>\n\n\n\n

Abstract<\/p>\n\n\n\n

Importance<\/strong>  The effects of rituximab on relapse of nephrotic syndrome in patients with adult-onset frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS) remain uncertain.<\/p>\n\n\n\n

Objective<\/strong>  To evaluate the effects of rituximab for patients with FRNS or SDNS.<\/p>\n\n\n\n

Design, Setting, and Participants<\/strong>  Multicenter, double-blind, randomized, placebo-controlled trial conducted at 13 centers in Japan. Adults with FRNS or SDNS who had urine protein of less than 0.3 g\/gCr were enrolled between September 1, 2020, and June 28, 2022. Final follow-up occurred on March 15, 2024.<\/p>\n\n\n\n

Interventions<\/strong>  Patients were randomized to receive either intravenous rituximab, 375 mg\/m2<\/sup> (n\u2009=\u200936), or placebo (n\u2009=\u200936) at weeks 1, 2, and 25. Patients were followed up for 49 weeks.<\/p>\n\n\n\n

Main Outcomes and Measures<\/strong>  The primary outcome was the proportion of patients who were free of relapse of nephrotic syndrome at 49-week follow-up. Relapse was defined as urine protein of at least 1 g\/gCr on 2 consecutive measurements.<\/p>\n\n\n\n

Results<\/strong>\u00a0\u00a0Among 72 randomized participants (mean age, 47.9 years; 56.1% female), 66 (92%) received the study drug at least once and were included in analyses. The relapse-free rate at week 49 was 87.4% (95% CI, 69.8%-95.1%) in the rituximab group and 38.0% (95% CI, 22.1%-53.8%) in the placebo group (P<\/em>\u2009<\u2009.001 by 1-sided log-rank test). One of 18 secondary outcomes was statistically significant (favoring rituximab). The median relapse-free time in the rituximab group was greater than 49.0 weeks and in the placebo group was 30.8 weeks. A stratified Cox model showed a hazard ratio for relapse of 0.16 (95% CI, 0.05-0.46;\u00a0P<\/em>\u2009<\u2009.001) in the rituximab group compared with the placebo group. The most common adverse effect was infusion reaction (13 [40.6%] in the rituximab group and 1 [2.9%] in the placebo group).<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Conclusions and Relevance<\/strong>  These results support use of rituximab to prevent relapse in adults with FRNS or SDNS.<\/p>\n\n\n\n

Trial Registration<\/strong>  Japan Registry of Clinical Trials: jRCT2051200045<\/a>; University Hospital Medical Information Network Clinical Trials Registry: UMIN000041475<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Original Investigation  Rituximab for Relapsing Ne […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29787"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29787"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29787\/revisions"}],"predecessor-version":[{"id":30108,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29787\/revisions\/30108"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}